UnitedHealth (UNH) Stock Surges 8% — Is the Medicare Relief Rally Genuine?

TLDR

• UNH gained 8.16% over the past week, including a single-day surge close to double digits
• The CMS finalized a 2.48% increase in 2027 Medicare Advantage reimbursement rates
• Bernstein lifted its price target to $411 and maintained its Buy rating
• HSBC upgraded UNH to Hold; Baird’s Michael Ha remains the only analyst with a Sell recommendation
• UNH is still down approximately 7% year-to-date and more than 50% below its 2024 peak

(SeaPRwire) –   UnitedHealth Group (UNH) enjoyed its strongest week in seven months, rising over 8% following an unexpected Medicare Advantage payment boost from the U.S. government.

UnitedHealth Group Incorporated (UNH)

The Centers for Medicare & Medicaid Services finalized a 2.48% increase in 2027 Medicare Advantage reimbursement rates— a significant improvement over an earlier proposal that would have kept rates nearly flat.

The announcement triggered a single-day rally of nearly double digits. Investors had been bracing for the worst, so the higher rate came as a genuine relief.

Medicare Advantage has been a core growth driver for UNH for over a decade. But rising medical costs and tighter government funding had started squeezing margins, making this ruling a much-needed positive development.

Bernstein acted promptly after the news, raising its price target on UNH to $411 while keeping its Buy rating intact.

Bernstein analysts noted that the CMS decision turns a potential 4% hit to 2027 earnings into an estimated 1.4% growth— a meaningful shift.

On the same day, HSBC analyst Sidharth Sahoo upgraded UNH to Hold. This was a measured move— not a full endorsement, but a sign that the stock’s risk profile had shifted.

One Holdout

Not all analysts are buying into the optimism. Baird’s Michael Ha maintained his Underperform rating, making him the only analyst with a sell-equivalent view among the 31 covering the stock.

Ha argues the payment increase may only be a temporary offset. He flagged that structural pressures on value-based care models haven’t gone away.

That’s a valid point worth keeping in mind. The Medicare Advantage business is still navigating a tricky environment, even with the improved rate.

The Bigger Picture

UNH recently projected a decline in 2026 revenue— which could mark its first annual contraction in over three decades. Enrollment is expected to shrink across commercial, Medicare, and Medicaid plans.

The stock is still down about 7% year-to-date and sits more than 50% below its 2024 peak. This week’s rally puts a dent in those losses, but the gap remains wide.

Still, Wall Street’s overall outlook is constructive. Of the 31 analysts covering UNH, 22 have Buy ratings. The average 12-month price target points to roughly 17% upside from current levels.

Optum, UNH’s health services arm covering pharmacy benefits and care delivery, continues to provide some earnings stability as the core insurance business faces headwinds.

Investors are now watching Q1 2026 earnings closely. Medical cost trends and any updated guidance on Medicare Advantage profitability will be the key items on the agenda.